Bio Medica Laboratories Summary
The firm is operating in the pharmaceutical industry and it specializes in the production of pharmaceutical parenteral formulations. The products produced by Bio Medica Laboratories include liquid and dry powder injectables for human and animal use. It uses the contract manufacturing business model where its primary customers are pharmaceutical firms and it makes its profit from B2B.
As far as the operational aspects of the company are concerned, the company manufactures injectables as per the contract manufacturing business model and earns consistent B2B revenues. The company's manufacturing capabilities, diversified products portfolio, and its customer base help it generate consistent revenues. It does not need a retail distribution network to grow.
Bio Medica Laboratories Ltd is launching an NSE SME book-built IPO with a face value of ₹10 per share and a price band of ₹132–₹139 per share. The total issue size is ₹52.43 Cr, comprising a fresh issue of ₹44.56 Cr and an offer for sale of ₹5.24 Cr, with ₹2.63 Cr reserved for the market maker. The issue is structured for QIB, NII, and Retail investors, and the tentative listing is on NSE SME on 29 May 2026.
Bio Medica Laboratories IPO Details:
Bio Medica Laboratories Limited Issue Management:
Narnolia Financial Services Ltd. acts as the book-running lead manager for Bio Medica Laboratories NSE SME IPO, managing underwriting and compliance.
Bio Medica Laboratories Limited IPO RTA (Registrar) Details:
Skyline Financial Services Pvt.Ltd. handles allotment, refunds, and demat credits - contact at 02228511022 or ipo@skylinerta.com.
Bio Medica Laboratories Limited IPO Allotment Status:
To check your IPO allotment status:
Visit the Skyline Financial Services Pvt.Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Bio Medica Laboratories SME IPO totals ₹52.43 Cr, comprising a fresh issue of ₹44.56 Cr and an Offer for Sale (OFS) of ₹5.24 Cr, with ₹2.63 Cr reserved for the market maker. The face value is ₹10 per share and the price band is ₹132–₹139 per share (book‑built issue on NSE SME).
Bio Medica Laboratories Limited IPO proceeds from the fresh issue will be deployed towards:
Bio Medica Laboratories IPO offers 37,72,000 equity shares (total issue ₹52.43 Cr, net offer to public ₹49.80 Cr after market‑maker reservation).
The anchor bidding for Bio Medica Laboratories Ltd. SME IPO is scheduled for 20th May 2026, one working day before the issue opens on 21st May 2026, and anchor investors will be allotted shares from the QIB portion (within the overall QIB tranch, as per SME‑IPO structure). As per the IPO reservation details, the QIB portion (including anchor) accounts for about 1.00% of the net issue size, with the remainder allocated to NII (48.98%) and Retail (50.01%).
Lock-in: The anchor allocation follows standard SME IPO norms, where 50% of the anchor shares are locked in for 30 days and the remaining 50% for 90 days from the listing date. The issue is scheduled to list on 29th May 2026 on NSE SME.
The anchor allocation details and investor list will be disclosed in the anchor book before the IPO opening. Narnolia Financial Services Ltd. is the Book Running Lead Manager (BRLM) to the issue, and the registrar for the IPO is Skyline Financial Services Pvt. Ltd.
Profitability at Bio Medica Laboratories Ltd. results from the concentration of the company on manufacturing, contract manufacturing, and supply of parenteral formulations of pharmaceuticals (liquid and dry powder injections) for human and animal consumption. Sources of income for the firm include contract manufacturing services (business to business), sale of generic and branded injections, and OTC products. Profitability is achieved through regulatory certification (GMP, GLP), quality control, ability to manufacture multiple products, and long-term customer relationships that help to sustain prices, repeat business, and efficiency.
On the financial front, Bio Medica has demonstrated solid growth and improving margins with revenues increasing drastically from ₹15.34 Cr (FY23) to ₹38.33 Cr (FY25), EBITDA jumping from ₹1.70 Cr to ₹15.21 Cr (FY23-FY25), and PAT increasing from ₹0.33 Cr to ₹9.79 Cr in the same period. Margins improved substantially (EBITDA and PAT marginally up to ~40% and ~25% respectively for FY25), while the return on equity and capital stood at 99.59% and 48.20% respectively (as of Mar-31,‑2025). Net worth increased to ₹17.12 Cr (consolidated, Nov‑30,‑2025).
Action Links:
To apply for Bio Medica Laboratories Limited IPO, open a demat account here
Bio Medica Laboratories Limited IPO Subscription Status: Check live subscription here
Bio Medica Laboratories Limited IPO GMP Update: Check latest grey market premium here
Bio Medica Laboratories Key Highlights:
Bio Medica Laboratories is a firm that operates in the pharmaceutical industry. It deals with production of parenteral preparations including liquid and dry powder injections for both human and veterinary uses. The company adopts a B2B contract manufacturing business approach. This implies that it produces injectable products for pharmaceutical firms.
Some of the core strengths of the company are multi-product manufacturing facility, GMP & GLP compliance, two manufacturing units in Indore (state of Madhya Pradesh), skilled promoters and management, and good client relationship that helps generate repeat orders and pricing consistency.
Recently, the company has scaled up its financial performance with the total income increasing from ₹15.34 Cr (FY23) to ₹38.33 Cr (FY25), while interim consolidated income increased to ₹28.63 Cr in nine months ending November 30, 2025.
Factors contributing to growth include: Demand for B2B contract manufacturing for injectable drugs from pharmaceuticals due to their high margins and regulation, Quality certification (GMP/GLP) and technical know-how to access institutional clients, Diversified product portfolio to support cross-selling and increased utilization of the manufacturing facility, Increased capacity and working capital investments for scaling operations without margin degradation.
Bio Medica Laboratories Risk Factors:
The risks of Bio Medica Laboratories Limited IPO are mentioned below:
Dependency on client contracts and demand cycles of the pharmaceutical industry; the loss of a key client would have an impact on revenue.
Risk associated with regulatory compliance (GMP/GLP); non-compliance may cause disruptions in business and sales.
Risk related to concentration if revenues come from a few large clients.
Liquidity risk associated with SME listing and potential increased volatility after listing.
Execution risk associated with capacity expansion, working capital management, and debt repayments.
Bio Medica Laboratories Expert Analysis:
Bio Medica’s SME IPO (NSE SME) involves a total issue size of ₹52.43 Cr with price band ₹132–139 (face value ₹10). The offer includes a fresh issue component and an offer-for-sale; proceeds target repayment of loans and enhancement of production capabilities.
Basic details of the IPO:
Type of IPO: Book‑built SME IPO (NSE SME)
Uses of funds: repay debt, expand manufacturing capacity, and general corporate purposes; moves that should support scale but carry execution and working-capital risks.
Anchor bidding: 18 May 2026 | Opens 21 May 2026 | Closes 25 May 2026 | Allotment 26 May 2026 | Listing 29 May 2026 (NSE SME).
Lead Manager: Narnolia Financial Services Ltd. | Registrar: Skyline Financial Services Pvt. Ltd.
Expert View on the IPO:
Bio Medica Laboratories is a niche player in injectable contract manufacturing with regulatory certifications and improving margins; comparable peers show lower ROE/P/E metrics, indicating Bio Medica’s current outperformance though with higher concentration and scaling risk.
Should you invest in Bio Medica Laboratories?
An investor interested in a small cap investment opportunity in an injectables contract manufacturing company operating in the niche space with high margin potential on the SME stock exchange should consider Bio Medica Laboratories’ IPO provided he is comfortable with the constraints of the SME market listing.
Consider investing when:
You are looking for exposure to an injectable contract-manufacturing business that is of high margin and niche in nature on the SME exchange.
You are willing to take the liquidity risks associated with the SME exchange and those associated with client concentration and capacity expansion execution risks.
You feel that the management will be able to maintain its clients and turn its capacity into higher utilization and higher revenues.
Do not invest when:
You want exposure to more established large cap pharmaceuticals or contract manufacturing firms.
You are concerned about SME listing liquidity and regulatory risk or client concentration risk.
You are not comfortable with scaling up operations quickly.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is for informative purposes and not investment advice.
Action Links:
To apply for Bio Medica Laboratories Limited IPO, open a demat account here
Bio Medica Laboratories Limited IPO Subscription Status: Check live subscription here
Bio Medica Laboratories Limited IPO GMP Update: Check latest grey market premium here
1. What is the Bio Medica Laboratories Limited IPO open and close date?
Bio Medica Laboratories Limited IPO opens on 21st May 2026 and closes on 25th May 2026. Anchor bidding is scheduled one working day before the issue opens (20th May 2026).
Track Bio Medica Laboratories Limited IPO subscription status live here from Finnpick.
2. What is the Bio Medica Laboratories Limited IPO price band and lot size?
The IPO is a book‑built SME issue with a price band of ₹132–₹139 per share (face value ₹10). Minimum lot size is 2,000 shares (2 lots = 4,000 shares for retail at the upper band = ₹5,56,000).
3. What is Bio Medica Laboratories Limited IPO total size?
The total issue size is ₹52.43 Cr (includes fresh issue of ₹44.56 Cr and offer for sale of ₹5.24 Cr; market maker portion ~₹2.63 Cr).
4. How to apply for the Bio Medica Laboratories Limited IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or apply ASBA by May 25, 4 PM. Monitor Bio Medica Laboratories Limited IPO subscription tracker here. Ensure your demat account is active and UPI mandate is approved before the closing time.
5. How to check Bio Medica Laboratories Limited IPO Allotment Status?
The allotment date is on May 26th and can be checked on Skyline Financial Services Pvt. Ltd. RTA portal using PAN/DP ID.
6. What is Bio Medica Laboratories Limited IPO GMP today and subscription status?
Current Grey Market Premium (GMP) stands at ₹0 as of May 19, indicating listing at the price range of ₹139 - check daily updates of Bio Medica Laboratories Limited IPO GMP trends here and live subscription status here from May 21st opening only on Finnpick.
7. What does Bio Medica Laboratories Limited specialize in?
The company manufactures parenteral pharmaceutical formulations (liquid and dry powder injectables) on a B2B contract‑manufacturing model, supplying generic, branded and OTC injectables for human and veterinary use.
8. When is the Bio Medica Laboratories Limited IPO listing date?
The Bio Medica Laboratories Limited IPO is scheduled to list on NSE SME on May 29, 2026, which is approximately T+2 after the basis of allotment on May 26, 2026.
9. What are the Bio Medica Laboratories Limited IPO proceeds utilization details?
The IPO proceeds will primarily be utilized towards: Repayment of loan (~₹6.50 Cr), enhancement of production capabilities (setting up new manufacturing facility ~₹28.50 Cr), and general corporate purposes (~₹35.00 Cr)
10. Who are the promoters of Bio Medica Laboratories Limited?
The promoters are Mr. Mukesh Mehta and Mr. Pradeep Mehta (pre‑IPO promoter holding ~99.99% as reported)
11. Should I apply for the Bio Medica Laboratories IPO?
Consider applying if you seek exposure to a niche, high‑margin injectable contract‑manufacturing business with improving profitability (strong EBITDA/PAT margins and high ROE/ROCE). Do not apply if you are averse to SME‑listing liquidity constraints, customer concentration, regulatory compliance risks, or execution risk tied to capacity expansion. This is informational and not investment advice; review the RHP/DRHP and consult a SEBI‑registered advisor.
